foxo4-dri peptide senolytic study Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Peptide inhibitors targeting FOXO4-p53 interactions

Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained

FoxO integration of insulin signaling with glucose and lipid metabolism

Certificate of Analysis (COA) Each batch of GHK-Cu is verified through HPLC and mass spectrometry analyses

C R Biol

Pinealon neuroprotective properties calm overactive neural circuits

Common Side Effects Flushing & GI effects: Flushing, nausea, cramping or lightheadedness can occur, especially if dosed too high or too fast